



NEWS RELEASE

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

2024-09-10

RADNOR, Pa.--(BUSINESS WIRE)-- **Marinus Pharmaceuticals, Inc.** (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET.

A link to the event can be accessed on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on **Facebook, LinkedIn** and **X** .

Investors

Sonya Weigle
Chief People and Investor Relations Officer
Marinus Pharmaceuticals, Inc.
sweigle@marinuspharma.com

Media



Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com

Source: Marinus Pharmaceuticals